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Ja´nos u. 53-54, H-1083 Budapest, Hungary; Email: gyorffy@kmplot.com)AbstractThe validation of prognostic biomarkers in large independent patient cohorts is a major bottleneck
in ovarian cancer research. We implemented an online tool to assess the prognostic value of the
expression levels of all microarray-quantified genes in ovarian cancer patients. First, a database
was set up using gene expression data and survival information of 1287 ovarian cancer patients
downloaded from Gene Expression Omnibus and The Cancer Genome Atlas (Affymetrix
HG-U133A, HG-U133A 2.0, and HG-U133 Plus 2.0 microarrays). After quality control and
normalization, only probes present on all three Affymetrix platforms were retained (nZ22 277). To
analyze the prognostic value of the selected gene, we divided the patients into two groups
according to various quantile expressions of the gene. These groups were then compared using
progression-free survival (nZ1090) or overall survival (nZ1287). A Kaplan–Meier survival plot
was generated and significance was computed. The tool can be accessed online at www.kmplot.
com/ovar. We used this integrative data analysis tool to validate the prognostic power of 37
biomarkers identified in the literature. Of these, CA125 (MUC16; PZ3.7!10K5, hazard ratio
(HR)Z1.4), CDKN1B (PZ5.4!10K5, HRZ1.4), KLK6 (PZ0.002, HRZ0.79), IFNG (PZ0.004,
HRZ0.81), P16 (PZ0.02, HRZ0.66), and BIRC5 (PZ0.00017, HRZ0.75) were associated with
survival. The combination of several probe sets can further increase prediction efficiency. In
summary, we developed a global online biomarker validation platform that mines all available
microarray data to assess the prognostic power of 22 277 genes in 1287 ovarian cancer patients.
We specifically used this tool to evaluate the effect of 37 previously published biomarkers on
ovarian cancer prognosis.Endocrine-Related Cancer (2012) 19 197–208Introduction
With a mortality of 8.4 per 100 000 women, ovarian
cancer is the most common cause of death among
gynecological malignancies (http://seer.cancer.gov)
with a 5-year survival rate of 10–30%. Relative to breast
cancer, the molecular characteristics of epithelial ovarian
cancer (EOC) are more heterogeneous. Despite extensive
research, clinical–pathological factors including tumor
stage, residual disease after surgery, histological type,
and tumor grade are still the most important featuresEndocrine-Related Cancer (2012) 19 197–208
1351–0088/12/019–197 q 2012 Society for Endocrinology Printed in Greatrelated to patient outcome. To date, only two biomarkers
have been approved by the Food and Drug Adminis-
tration (FDA) for monitoring patients with EOC: CA125
(MUC16; Gadducci et al. 1995, 2004, Cooper et al. 2002,
Riedinger et al. 2006) andHE4 (WFDC2; Huhtinen et al.
2009, Moore et al. 2009, 2010).
Several additional genes have been suggested
as potential biomarkers for the progression of EOC.
Low expression of p21 (Ferrandina et al. 2000,
Plisiecka-Halasa et al. 2003, Bali et al. 2004), baxBritain
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B Gyo˝rffy et al.: Survival analysis in ovarian cancer(Tai et al. 1998, Skirnisdottir et al. 2001), and hTERT
(Brustmann 2005) and high expression of survivin (Sui
et al. 2002), VEGFR (Hefler et al. 2006), p53 (Buttitta
et al. 1997, Reles et al. 2001), human kallikrein 6
(Diamandis et al. 2003), human kallikrein 10 (Luo
et al. 2001), Interleukin 6 (Scambia et al. 1995), p27
(Newcomb et al. 1999, Masciullo et al. 2000,
Korkolopoulou et al. 2002, Schmider-Ross et al.
2006), cyclin D1 (Bali et al. 2004, Barbieri et al.
2004), cyclin D3 (Levidou et al. 2007), cyclin E (Sui
et al. 2001, Farley et al. 2003, Rosen et al. 2006,
Bedrosian et al. 2007), Bcl-xL (Materna et al. 2007),
cIAP (Psyrri et al. 2006), and ERBB1 (Skirnisdottir
et al. 2004, Psyrri et al. 2005) could represent
prognostic variables for poor clinical outcome. In
addition, the genome-wide investigation of adequate
clinical cohorts delivers unprecedented amount of
potential new biomarkers (Denkert et al. 2009).
However, most of these potential biomarkers have
neither been validated in multivariate analyses nor
was their discriminative power validated in large
clinical cohorts. Even more alarmingly, many reports
have questioned or rejected a correlation between a
proposed biomarker and clinical outcome. Doubts were
raised regarding the markers CA125 (Cruickshank
et al. 1987, van der Burg et al. 1988, Rustin et al.
1989, Sevelda et al. 1989), cyclin D1 (Masciullo
et al. 1997, Dhar et al. 1999), p16 (Milde-Langosch
et al. 2003, Khouja et al. 2007), p21 (Baekelandt et al.
1999, Levesque et al. 2000, Schuyer et al. 2001),
p27 (Schmider et al. 2000), p53 (Smith-Sorensen et al.
1998, Wang et al. 2004, Green et al. 2006), Bcl-xl
(Baekelandt et al. 2000), cIAP (Kleinberg et al.
2007), survivin (Cohen et al. 2003, Ferrandina et al.
2005), hTERT (Wisman et al. 2003, Widschwendter
et al. 2004), ERBB1 (Berchuck et al. 1991, Meden et al.
1995, Nielsen et al. 2004), and ERBB2 (Rubin
et al. 1993, Meden et al. 1995, Ross et al. 1999,
Nielsen et al. 2004, Riener et al. 2004).
Given the large number of potential biomarkers for
EOC, the immediate challenge is to validate the most
robust candidates eligible for further investigation.
Recent advances in genomic technologies together
with powerful bioinformatic tools can enable us to
deliver this prerequisite. We recently developed an
online biomarker validation tool using microarray data
of 2000 breast cancer patients (Gyorffy et al. 2010).
In this, the expression of a selected gene can be used
to split patients into groups, and the proportional
survival of these groups is compared to each other.
In this study, our aim was to implement an online
survival analysis tool for the rapid assessment of
prognosis-related genes in ovarian cancer and to test198the validity of previously proposed biomarkers.
Furthermore, we also developed additional analysis
options including the computation of multigenic
prognosis predictors and the option of grouping
patients based on applied treatment protocols.Materials and methods
Collection of ovarian cancer microarray data sets
We searched Gene Expression Omnibus (GEO; http://
www.ncbi.nlm.nih.gov/geo/) and The Cancer Genome
Atlas (TCGA; http://cancergenome.nih.gov) to ident-
ify data sets suitable for the analysis. In this, the
keywords ‘ovarian’, ‘cancer’, ‘survival’, ‘gpl96’,
‘gpl570’, and ‘gpl571’ were used. Only publications
with available raw microarray gene expression data,
clinical survival information, and at least 20 patients
were included. Only three microarray platforms,
GPL96 (Affymetrix HG-U133A), GPL570 (Affymetrix
HG-U133 Plus 2.0), and GPL571/GPL3921 (Affyme-
trix HG-U133A 2.0), were considered because they are
frequently used and because these particular arrays
have 22 277 probe sets (representing 13 435 unique
genes) in common. The use of almost identical
platforms and identical probe sets is vital because
different platforms for gene expression profiling
measure expression of the same gene with varying
accuracy, on different relative scales, and with diverse
dynamic ranges (Tan et al. 2003). Finally, we
controlled all samples using the ranked expression of
all genes to identify repeatedly published microarrays.Setup of server for online survival calculation
The raw.CEL files were MAS5 normalized in the R
statistical environment (www.r-project.org) using the
affy Bioconductor library (Gautier et al. 2004). MAS5
can be applied to individual chips, making future
extensions of the database uncomplicated. Further-
more, MAS5 ranked among the best normalization
methods when compared with the results of RT-PCR
measurements in our recent study (Gyorffy et al. 2009).
For the analysis, only probes measured on GPL96,
GPL570, and GPL571/GPL3921 were retained
(nZ22 277). At this stage, we performed a second
scaling normalization to set the average expression on
each chip to 1000. Although this technique cannot
remove all, but it can significantly reduce batch effects
(Sims et al. 2008). We integrated the gene expression
and clinical data using PostgreSQL, an open-source
object-relational database system (www.postgresql.
org). Data security is ensured through PostgreSQLwww.endocrinology-journals.org
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Endocrine-Related Cancer (2012) 19 197–208permissions that are imposed on individual tables in the
project databases.
The KMplot web application can be reached in a
platform-independent user interface. The interactivity
of the service is increased by the usage of JavaScript
and Ajax technologies. The server is hosted on
Debian Linux (www.debian.org) and is powered by
Apache (www.apache.org). he server-side scripts
were developed in hypertext preprocessor (PHP),
which controls the analysis requests and delivers the
results. Open Database Connectivity is used as a
middleware layer between the R and the PostgreSQL
database via the RODBC package (cran.r-project.org/
packageZRODBC). The package ‘survival’ is used
to calculate and plot Kaplan–Meier survival curves,
and the number-at-risk is indicated below the main
plot. Hazard ratio (HR; and 95% confidence intervals)
and logrank P are calculated and displayed. The central
server for the Kaplan–Meier plotter for ovarian cancer
can be reached at www.kmplot.com/ovar.
Probe set options
We also implemented a set of probe-set-related
options, including the option to use all probe sets
available for a given gene on the microarray
simultaneously and to use a combined expression of
several probe sets. Using this option, it is possible to
assess the effect of the mean expression of gene
combinations on survival.
Inaddition,beeswarmplotcanbedrawnusing thebees-
warm package (www.cbs.dtu.dk/weklund/beeswarm/).
The bee swarm plot is capable of visualizing gene
expression as nonoverlapping points in a one-dimensional
scatter plot. A bee swarm plot can be used to quickly
identify outlier samples and genes with bimodal
distribution.
Validation of previously published EOC
biomarkers
A PubMed search was performed using the keywords
‘ovarian cancer’, ‘survival’, ‘biomarker’, and ‘gene
expression’ to identify genes described in the literature
as potential EOC biomarkers. Then, using PubMed
gene, we added a unique gene symbol for each of the
genes and identified the corresponding Affymetrix
probe set IDs. The capability of these genes to predict
survival was measured by using the probe set IDs in the
online analysis tool.
In the combination of several markers, their mean
expression is first computed for each sample. Then, the
median of these is used for splitting the patients into
cohorts during the analysis.www.endocrinology-journals.org 199
Table 2 The association between prognostic markers and progression-free survival. The patients were divided into two groups as
having higher or lower expression as compared to the median. The markers were analyzed in subsets of patients with equivalent
clinical characteristics to the cohorts in which the association has previously been described
Symbol Gene Reference Survival
Analyzed in
the cohort of
Affymetrix
ID Q HR P
CA(MUC 16)125 CA 125 Gadducci et al. 1995,
Cooper et al. 2002,
Gadducci et al. 2004,
Riedinger et al. 2006
PFS All patients 220196_at 2 NS NS
201384_s_at 1 1.3 0.0003*
201383_s_at 1 1.4 3.7!10K5*,a
KRT19 Cytokeratin 19 Tempfer et al. 1998,
Gadducci et al. 2001
PFS DebulkZsubopt. 201650_at 1 NS NS
KLK6 Kallikrein 6 Diamandis et al. 2003 PFS All patients 216699_s_at 2 0.79 0.002*
204733_at 1 NS NS
KLK10 Kallikrein 10 Luo et al. 2001 PFS StageZ3C4 209792_s_at 1 NS NS
215808_at 3 NS NS
IL6 Interleukin 6 Scambia et al. 1995 OS All patients 205207_at 2 NS NS
IL7 Interleukin 7 Lambeck et al. 2007 OS All patients 206693_at 3 NS NS
IFNG g-Interferon Marth et al. 2004 PFS All patients 210354_at 3 0.81 0.004*
FAS sFas Hefler et al. 2000,
Konno et al. 2000
PFS All patients 204780_s_at 1 1.2 0.017
204781_s_at 1 NS NS
212218_s_at 1 0.84 0.024
215719_x_at 2 NS NS
216252_x_at 2 NS NS
217006_x_at 3 NS NS
VEGFR VEGFR Hefler et al. 2006 OS All patients 203934_at 2 1.2 0.064
CCND1 Cyclin D1 Bali et al. 2004, Barbieri
et al. 2004
OS StageZ3C4 208711_s_at 1 NS NS
208712_at 1 NS NS
CCND3 Cyclin D3 Levidou et al. 2007 OS All patients 201700_at 1 NS NS
CCNE Cyclin E Sui et al. 2001, Farley
et al. 2003, Rosen
et al. 2006, Bedrosian
et al. 2007
OS DebulkZsubopt. 213523_at 2 NS NS
205034_at 2 NS NS
211814_s_at 3 NS NS
P(CDK N2B)15 p15 Kudoh et al. 2002 PFS All patients 204599_s_at 1 NS NS
212857_x_at 1 1.3 0.0005*
214512_s_at 1 1.2 0.01
221727_at 3 NS NS
218708_at 1 NS NS
P(CDK N2A)16 p16 Katsaros et al. 2004,
Kommoss et al. 2007
PFS DebulkZsubopt. 207039_at 2 0.66 0.002*
209644_x_at 1 NS NS
211156_at 3 0.69 0.009
CDKN1A p21 Ferrandina et al. 2000,
Plisiecka-Halasa et al.
2003, Bali et al. 2004
PFS HistologyZ
serous
202284_s_at 1 NS NS
CDKN1B p27 Newcomb et al. 1999,
Masciullo et al. 2000,
Korkolopoulou et al.
2002, Schmider-Ross
et al. 2006
PFS All patients 209112_at 1 1.4 5.4!10K5*,a
RB1 pRB Dong et al. 1997,
Konstantinidou et al.
2003
OS StageZ1 203132_at 1 NS NS
211540_s_at 3 NS NS
E2F1 E2F1 Suh et al. 2008 PFS All patients 2028_s_at 1 0.83 0.017
3 NS NS
E2F2 E2F2 Reimer et al. 2007 PFS All patients 207042_at 3 0.86 0.037
E2F4 E2F4 Reimer et al. 2007 PFS All patients 202248_at 3 0.85 0.034
38707_r_at 1 NS NS
TP53 p53 Buttitta et al. 1997, Reles
et al. 2001
PFS StageZ3C4 211300_s_at 2 NS NS
201746_at 1 0.84 0.075
TP73 p73 Becker et al. 2006 OS All patients 220804_s_at 3 NS NS
BAX bax Tai et al. 1998,
Skirnisdottir et al. 2001
PFS TherapyZ
contains Taxol
208478_s_at 2 NS NS
211833_s_at 2 NS NS
B Gyo˝rffy et al.: Survival analysis in ovarian cancer
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Table 2 continued
Symbol Gene Reference Survival
Analyzed in
the cohort of
Affymetrix
ID Q HR P
BCL2L1 Bcl-xl Materna et al. 2007 PFS All patients 212312_at 1 0.86 0.04
215037_s_at 2 NS NS
206665_s_at 3 NS NS
BIRC2 cIAP Psyrri et al. 2006 OS StageZ3C4 202076_at 1 NS NS
BIRC5 Survivin Sui et al. 2002 PFS All patients 210334_x_at 2 0.75 0.00017*
202094_at 2 0.84 0.018
202095_s_at 1 0.84 0.018
TERT hTERT Brustmann 2005 OS HistologyZ
serous
207199_at 3 NS NS
EGFR ERBB1 Skirnisdottir et al. 2004,
Psyrri et al. 2005
PFS StageZ1C2 201983_s_at 1 NS NS
201984_s_at 1 NS NS
211551_at 2 NS NS
210984_x_at 3 NS NS
211550_at 3 NS NS
211607_x_at 3 NS NS
ERBB2 ERBB2 Lassus et al. 2004 PFS HistologyZ
serous
210930_s_at 3 NS NS
216836_s_at 1 NS NS
MET c-Met Sawada et al. 2007 OS StageZ3C4 217828_at 1 NS NS
203510_at 1 NS NS
211599_x_at 1 NS NS
213807_x_at 2 NS NS
213816_s_at 3 NS NS
MMP2 MMP-2 Torng et al. 2004 PFS HistologyZ
endom.
201069_at 1 0.33 0.05
MMP9 MMP-9 Sillanpaa et al. 2007 OS StageZ1 203936_s_at 1 NS NS
MMP14 MT1-MMP Kamat et al. 2006 OS StageZ2C3C4 160020_at 1 NS NS
202828_s_at 1 NS NS
202827_s_at 2 NS NS
217279_x_at 3 NS NS
WFDC2 (HE4) Epididymis
protein 4
Huhtinen et al. 2009,
Moore et al. 2009,
2010
PFS All patients 203892_at 1 NS NS
SERPINB5 Maspin Secord et al. 2006 PFS DebulkZsubopt. 204855_at 1 NS NS
BRCA1 BRCA1 Thrall et al. 2006 OS All patients 211851_x_at 3 0.82 0.01
204531_s_at 2 NS NS
ERCC1 ERCC1 Darcy & Tian 2007 PFS StageZ3 203719_at 1 NS NS
TherapyZ
TaxCPlat
203720_s_at 1 NS NS
PFS, progression-free survival; OS, overall survival, HR, hazard ratio; Q, quality score for the probe set as measured after
normalization across the entire data set (1, average expression over 500 or maximal expression over 1000; 2, intermediate probes;
3, average expression below 100); NS, not significant (significance over 0.05). *bold indicates P!0.005.
aSee Kaplan–Meier plots in Fig. 1.
Endocrine-Related Cancer (2012) 19 197–208Results
Construction of combined ovarian cancer
microarray database
We identified 1287 unique patients in eight data sets
meeting our criteria in GEO and TCGA. In the GSE3149
data set, we found two samples repeatedly published
(GSM70546ZGSM70547 and GSM70511ZGSM
70512). As for these samples the unique recognition
of the appropriate clinical information was not possible,
we removed them from the final database. Of the above,
72% have serous and 2% have endometrioid tumors.
Patients are distributed across stage 1 (nZ34, 3.6%),www.endocrinology-journals.orgstage 2 (nZ122, 13%), stage 3 (nZ672, 71.7%), and
stage 4 (nZ109, 11.6%). Debulking was optimal
(residual tumor !1 cm) in 674 out of 1119 patients.
The median overall survival is 31.0 months, 1090 patients
have progression-free survival data, and 1287 have
overall survival data. (note: some publications report
‘disease-free survival’ (Konstantinopoulos et al. 2010) or
‘relapse-free survival’ (Tothill et al. 2008) instead
of ‘progression-free survival’. These were merged as
‘progression-free survival’ to enable a meta-analysis of
the complete database.). A summary of the clinical
characteristics of the patients in each data set used in
the analysis is shown in Table 1.201
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Figure 1 Survival plots depicting the good prognostic effect
on progression-free survival of the lower expression of
CA125 (A, 201383_s_at), CDKN1B (B, 209112_at), and P15
(C, 212857_x_at). Classification using the mean expression
of two genes (CA125CCDKN1B) with a cutoff at the lower
quartile results in increased discriminative power (D).
B Gyo˝rffy et al.: Survival analysis in ovarian cancer
202Setup of online survival analysis platform
The Kaplan–Meier plot shows the association between
the investigated marker and survival in which the
samples are grouped according to the median (or upper
or lower quartile) expression of the selected gene.
Before running the analysis, the patients can be filtered
using stage, histology, grade, and treatment parameters
including debulking status and applied chemotherapy.
In addition, as an alternative to progression-free
survival, overall survival can also be investigated.
Since there is an already established biomarker
(CA125), a clinician might be interested in a specific
clinical cohort of patients having low CA125 levels.
Therefore, we added an additional filtering option in
which only patients having an average CA125
expression (average of the two reliable probe sets)
below the lower quartile of all patients are included.
We must note that while this study measured tissue
levels of CA125, the FDA-approved test for ovarian
cancer is serum based.
Validation of previously published EOC
biomarkers
Markers of ovarian cancer prognosis have been
identified using literature search. We computed
Kaplan–Meier plots for 37 proposed biomarkers to
assess their effect on prognosis (for the complete
results see Table 2 and Fig. 1). All biomarkers were
investigated in the same cohort in which they were
discovered. High significance was achieved for CA125,
KLK6, IFNG, P15, P16, CDKN1B, and BIRC5. In
addition, we have also run the analysis for predicting
progression-free survival in all patients.
In an effort to improve accuracy, a pair-wise
combination of the three best performing probe sets
was assessed independently. The combination of CA125
and CDKN1B with a cutoff at the lower quartile resulted
in classification significance superior to the power of the
markers independently (HRZ1.5 and PZ5.4!10K6 vs
HRZ1.4, PZ3.7!10K5 and HRZ1.4, PZ5.4!10K5
for CA125 and CDKN1B, respectively, see Table 2
and Fig. 1).Discussion
The validation of prognostic biomarkers is a major
bottleneck in ovarian cancer research. Here, we
combined multiple large microarray data sets to
increase the statistical power for a meta-analysis of
22 277 genes. We developed a freely accessible online
tool to estimate the prognostic value of any selected
gene in a large cohort of clinical patients. After dividingwww.endocrinology-journals.org
Endocrine-Related Cancer (2012) 19 197–208the patients into two groups based on the expression
of the selected gene, a Kaplan–Meier plot is generated.
The implemented computations are performed in real
time on our server. This enables seamless future
extension using new data sets or new filtering options.
We have integrated data sets from GEO and TCGA –
w40% of samples used by www.kmplot.com/ovar are
from the TCGA repository. For the TCGA samples
alone, there is an option to perform analyses in the
caIntegrator website (https://caintegrator.nci.nih.gov).
The samples in TCGA are open access or restricted
(access is granted to NIH staff and to eRA Commons
principal investigators) – however, the Affymetrix
HG-U133 microarray profiles for the ovarian cancer
patients are publicly available. We plan to continu-
ously incorporate new GEO data sets as well as new
TCGA samples in www.kmplot.com.
In contrast to breast cancer, where several already
approved markers are in clinical use, in ovarian cancer
only minimal progress has been made in recent years.
When investigating the previously proposed bio-
markers, we found that only few genes are actually
capable of predicting outcome in our combined data
set: CA125, P15, KLK6, IFNG, P16, CDKN1B, and
BIRC5. Of these, CA125 and CDKN1B resulted in very
robust significance. These results may reflect the high
genetic heterogeneity of ovarian cancer (Gyorffy et al.
2008) and emphasize the importance of potential
improvements in prognosis.
The most extensively studied marker for EOC is
CA125 (Gadducci et al. 1995, 2004, Cooper et al.
2002, Riedinger et al. 2006), and determining its
concentration in serum is essential for monitoring
ovarian cancer progression. Fifty percent increase in
serum CA125 level has been correlated to progression,
and present progression definition of the Gynecologi-
cal Cancer Intergroup defines progression based on two
elevated serum CA125 levels. According to our results,
tumor level of CA125 gene was able to predict later
clinical outcome. Notably, we observed two different
probe sets representing CA125 as significant. A third
probe set did not show significant prognostic power,
but it has also displayed low quality in terms of average
expression as compared to the probe sets with
significant prognostic power.
The role of the cell cycle control gene p27 (CDKN1B)
as a prognostic marker in ovarian cancer was suggested
in several studies (Newcomb et al. 1999, Masciullo
et al. 2000, Korkolopoulou et al. 2002, Schmider-Ross
et al. 2006). In addition, numerous recent analyses
also confirmed its role in 205 (Lee et al. 2011), 131
(Skirnisdottir et al. 2011), and 339 (Duncan et al.
2010) patients. p27 is measured by only one probe set onwww.endocrinology-journals.orgthe microarrays, and this probe set delivered high
prognostic power in our analysis.
P15 is a tumor suppressor gene previously associ-
ated with ovarian cancer progression in 45 patients
(Kudoh et al. 2002). The methylation status of P15 has
also been investigated but was not an independent
prognostic factor in 145 patients (Tam et al. 2007).
One of the probe sets measuring P15 (212857_x_at)
delivered a high prognostic potential.
To this point, we have investigated the prognostic
power of individual probe sets. However, recent
reports based on genomic technologies use not only
single selected genes, but also a combination of these.
In addition, some of the markers are not related to
ovarian cancer prognosis in general, but have
discriminative potential in one of the subgroups, or
are related to different treatment regimens. While the
evaluation of all potential markers and all eligible
combinations is beyond the scope of this study, our
online tool was set up exactly to enable researchers to
perform these tests on our database.
In summary, we reviewed previously reported
biomarkers of ovarian cancer prognosis and assessed
their performance in a meta-analysis of 1297 ovarian
cancer patients. We also developed an online biomarker
validation platform to mine all available microarray data
to assess the prognostic power of 22 277 genes.Declaration of interest
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